INNOVATE Corp.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- INNOVATE Corp. (NYSE: VATE) operates as a diversified holding company with subsidiaries focused on infrastructure, life sciences, and spectrum segments primarily in the United States; its infrastructure unit through DBM Global Inc. provides fully integrated construction and professional services including design-assist, modularization, fabrication and erection of structural steel, heavy steel plate, trusses and girders, heavy equipment installation, as well as facility maintenance and shutdown services for critical sectors such as infrastructure and energy; the life sciences segment encompasses Pansend Life Sciences developing innovative healthcare technologies to address unmet needs, R2 Technologies offering an FDA-cleared device to soothe, brighten skin and treat visible signs of aging caused by inflammation in the global aesthetic dermatology market, and MediBeacon providing the FDA-approved Transdermal GFR System (TGFR), a point-of-care product for assessing kidney function in patients with normal or impaired renal function targeting a $7 billion market; the spectrum segment operates through HC2 Broadcasting Holdings Inc. and subsidiaries, owning and managing one of the largest broadcast station groups in the U.S. with 256 stations in 106 markets and 2.3 billion MHz POPs of spectrum for over-the-air broadcasting. Founded in 1994 and headquartered at 295 Madison Avenue, 12th Floor, New York, New York, the company, formerly known as HC2 Holdings, Inc. and tracing roots to Primus Telecommunications Group, rebranded to INNOVATE Corp. in September 2021 to emphasize innovative growth businesses across its portfolio serving industrial, healthcare, biotechnology, and media markets. In a significant recent development, INNOVATE Corp. completed a comprehensive debt refinancing in August 2025, restructuring 81.7% of its total outstanding principal debt as of June 30, 2025, by exchanging $328.1 million of existing senior secured notes for new 10.500% Senior Secured Notes due 2027, $48.7 million convertible senior notes for new 9.5% Convertible Senior Secured Notes, amending various credit facilities, and exchanging preferred stock for additional note principal resulting in a $43.0 million CGIC note, while extending maturities on its revolving credit agreement to September 2026, CGIC note to April 2027, Spectrum Notes to September 2026, and R2 Technologies note to August 2026 to enhance financial flexibility.
Company News
INNOVATE Announces Closing of the Sale of a Controlling Interest in its Broadcasting Segment to CONX
VATE Q2 Earnings Improve Y/Y as Infrastructure Revenues Surge
MediBeacon® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology
IES Holdings to Acquire DBM Global
INNOVATE Agrees to $650 Million Sale of DBM Global to IES Holdings
INNOVATE Q2 Earnings Call Highlights
INNOVATE Corp. (VATE) Q2 2026 Earnings Call Prepared Remarks Transcript
INNOVATE Corp. to Report Second Quarter 2026 Results on August 6th
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend
INNOVATE Announces Successful Closing of Broadcasting Refinancing and Agrees to Partial Sale of Broadcasting
INNOVATE Q1 Loss Narrows Y/Y on Infrastructure, AI Project Demand
INNOVATE Q1 Earnings Call Highlights
INNOVATE Corp. (VATE) Q1 2026 Earnings Call Prepared Remarks Transcript
INNOVATE Corp. Announces First Quarter 2026 Results
INNOVATE Corp. to Report First Quarter 2026 Results on May 14th
INNOVATE (NYSE:VATE) & Great Elm Group (NASDAQ:GEG) Financial Review
Comparing Livento Group (OTCMKTS:NUGN) and INNOVATE (NYSE:VATE)
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend
MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation
INNOVATE Corp. (VATE) Q4 2025 Earnings Call Prepared Remarks Transcript